BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27569942)

  • 1. Safety of Monitoring Viral and Liver Function Markers in Patients With Prior Resolved Hepatitis B Infection After Kidney Transplantation.
    Maekawa H; Yazawa M; Koitabashi K; Imai N; Kawarazaki H; Nakazawa R; Sasaki H; Chikaraishi T; Shibagaki Y
    Transplant Proc; 2016; 48(6):2046-9. PubMed ID: 27569942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
    Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
    Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
    Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
    Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
    Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
    Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients.
    Lee J; Park JY; Huh KH; Kim BS; Kim MS; Kim SI; Ahn SH; Kim YS
    Nephrol Dial Transplant; 2017 Apr; 32(4):722-729. PubMed ID: 28339910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: Risk factors and the safety and efficacy of preemptive therapy.
    Mei T; Noguchi H; Hisadome Y; Kaku K; Nishiki T; Okabe Y; Nakamura M
    Transpl Infect Dis; 2020 Apr; 22(2):e13234. PubMed ID: 31856328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis.
    Yin S; Zhang F; Wu J; Lin T; Wang X
    PLoS Med; 2023 Mar; 20(3):e1004196. PubMed ID: 36920988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
    Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation.
    Zhang JW; Zhang XZ; Sun YL; Long B; Wang XZ; Li XD
    BMC Infect Dis; 2019 Jan; 19(1):57. PubMed ID: 30651070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
    Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
    Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
    Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Zhu JJ; Wang SY; Qiu DK
    J Dig Dis; 2013 Aug; 14(8):439-45. PubMed ID: 23638710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of de novo hepatitis B virus infection in pediatric hepatitis B core antibody positive liver graft recipients under prophylactic therapy.
    Dong C; Song Z; Chen J; Ma N; Meng X; Sun C; Duan K; Bi B; Wang K; Qin H; Han C; Yang Y; Zhang F; Zheng W; Gao W
    J Gastroenterol Hepatol; 2020 May; 35(5):827-832. PubMed ID: 31609494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study.
    Chancharoenthana W; Townamchai N; Pongpirul K; Kittiskulnam P; Leelahavanichkul A; Avihingsanon Y; Suankratay C; Wattanatorn S; Kittikowit W; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
    Am J Transplant; 2014 Dec; 14(12):2814-20. PubMed ID: 25395260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
    Knöll A; Boehm S; Hahn J; Holler E; Jilg W
    J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.